Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Danggui Sini is a Traditional Chinese Medicine (TCM) formula, often administered as a granule or decoction, primarily used to treat conditions associated with Cold Coagulation and Blood Stasis in TCM theory. In modern clinical research, it is being investigated for its potential to prevent and treat oxaliplatin-induced peripheral neuropathy (OIPN) in patients with colorectal cancer. The formula typically consists of seven herbs: *Angelica sinensis* (Danggui), *Cinnamomum cassia* (Guizhi), *Paeonia lactiflora* (Shaoyao), *Asarum sieboldii* (Xixin), *Glycyrrhiza uralensis* (Gancao), *Tetrapanax papyrifer* (Tongcao), and *Ziziphus jujuba* (Dazao). Its mechanism is thought to involve anti-inflammatory, antioxidant, and neuroprotective effects, potentially by modulating neurotrophic factors and reducing oxidative stress in peripheral nerves.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on danggui sini.